-
-
-
-
-
-
-
Innovent and HUTCHMED Say FRUSICA-2 Phase 2/3 Study of Sintilimab and Fruquintinib Combination Met Primary Endpoint
-
-
-
-
-
-
-
Innovent Updates the Results from the ORIENT-31 Study of Sintilimab Plus Chemotherapy With or Without Bevacizumab in Patients with EGFR-TKI failed EGFR-mutated Non-Squamous Non-Small Cell Lung Cancer
-
-
-
-
-
-
-
Innovent and Lilly Jointly Announce Results of Seven Clinical Studies of TYVYT® (sintilimab injection) to Be Presented at the ESMO ASIA Congress 2020
68,529 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

